Study finds how adding ribociclib to hormone therapy improve

California, June 2: A study discovered that when ribociclib, a targeted therapy medicine, is added to hormone treatment, patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a substantial invasive disease-free survival advantage.

Related Keywords

United States , California , American , Dennis Slamon , Maniesh Paul , American Society Of Clinical Oncology Annual Meeting , Jonsson Comprehensive Cancer Center , Jonsson Cancer Center , Jonsson Comprehensive Cancer Centre , Comprehensive Cancer Centre , American Society , Clinical Oncology Annual Meeting , Comprehensive Cancer , Study Finds How Adding Ribociclib To Hormone Therapy Improves Results In Early Breast Cancer Patients , Study , Kinds , Redding , Ribociclib , Ormone , Therapy , Mproves , Results , Early , Breast , Dancer , Patients ,